


Alzheimer's Clinical Trials Across the United States of America: A Cross-Sectional Analysis of Site Distribution and Disease Burden

Lina Petrossian, BS¹, Carla Margossian², Saylor Towsley³, Zella Margossian³, Sarmen Sarkissian, MD³

¹School of Medicine, California University of Science and Medicine, Colton, CA, USA

²University at Buffalo, Buffalo, NY, USA

³Armenian American Medical Society, Glendale, CA, USA

INTRODUCTION	METHODS	RESULTS	CONCLUSIONS	FIGURES
Alzheimer’s remains the most common form of dementia nationwide. Participation in clinical trials is critical for the advancement of new treatments. However, equitable access to therapies depends on the geographic distribution of trial sites. Disparities in trial availability can limit participation for patients living in states with high Alzheimer’s mortality, but few research opportunities. According to the CDC, Mississippi has the highest rate of Alzheimer’s mortality. These patterns raise questions about whether the availability of trials aligns with the national burden of disease.	We searched ClinicalTrials.gov for interventional Alzheimer’s clinical trials that were looking for participants. Locations were manually extracted from each trial and categorized by state. Using ClinicalTrials.gov, we compiled the total number of sites per city. We generated heatmaps to visually compare site distribution with Alzheimer’s mortality.	A total of 1225 sites from 556 trials were identified across the USA. On a per 100,000 population basis, Mississippi had 0.2 trial sites. <1% of sites were located in Mississippi, despite their disproportionately high Alzheimer’s burden. A chi-square goodness-of-fit test confirmed a statistically significant mismatch between Alzheimer’s mortality and trial site distribution across the nation (p<0.0000001).	To address the mismatch between disease burden and research opportunities, there is a need to expand Alzheimer’s clinical trials in high-mortality states to ensure that patients in areas most affected by Alzheimer’s have access to interventional therapies.	 Alzheimer's Clinical Trial Sites per 100,000 Total Population Alzheimer's Disease Deaths per 100,000 Total Population (Age Adjusted Mortality Rate) CONTACT Lina Petrossian: lina.petrossian@md.cusm.edu  ALZHEIMER'S ASSOCIATION AAIC 26